Nektar Therapeutics (NKTR)
USD 0.56
(-6.09%)
USD 0.56
(-6.09%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 398.03 Million USD | -43.99% |
| 2022 | 710.6 Million USD | -36.39% |
| 2021 | 1.11 Billion USD | -27.4% |
| 2020 | 1.53 Billion USD | -22.18% |
| 2019 | 1.97 Billion USD | -8.04% |
| 2018 | 2.15 Billion USD | 322.54% |
| 2017 | 508.86 Million USD | -10.55% |
| 2016 | 568.87 Million USD | 13.31% |
| 2015 | 502.06 Million USD | 13.69% |
| 2014 | 441.62 Million USD | 1.63% |
| 2013 | 434.52 Million USD | -12.71% |
| 2012 | 497.79 Million USD | -17.93% |
| 2011 | 606.55 Million USD | 16.37% |
| 2010 | 521.22 Million USD | -9.43% |
| 2009 | 575.51 Million USD | 2.67% |
| 2008 | 560.53 Million USD | -22.7% |
| 2007 | 725.1 Million USD | -5.61% |
| 2006 | 768.17 Million USD | -10.53% |
| 2005 | 858.55 Million USD | 15.25% |
| 2004 | 744.92 Million USD | 20.77% |
| 2003 | 616.78 Million USD | 1.67% |
| 2002 | 606.63 Million USD | -9.08% |
| 2001 | 667.24 Million USD | 5.99% |
| 2000 | 629.54 Million USD | 177.57% |
| 1999 | 226.8 Million USD | 68.63% |
| 1998 | 134.49 Million USD | 12.3% |
| 1997 | 119.76 Million USD | 188.58% |
| 1996 | 41.5 Million USD | 78.88% |
| 1995 | 23.2 Million USD | 34.88% |
| 1994 | 17.2 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 396.01 Million USD | -0.51% |
| 2024 Q2 | 343.33 Million USD | -13.3% |
| 2023 Q2 | 494.27 Million USD | -12.01% |
| 2023 Q1 | 561.74 Million USD | -20.95% |
| 2023 FY | 398.03 Million USD | -43.99% |
| 2023 Q3 | 442.24 Million USD | -10.53% |
| 2023 Q4 | 398.03 Million USD | -10.0% |
| 2022 Q2 | 861.98 Million USD | -15.83% |
| 2022 Q3 | 781 Million USD | -9.39% |
| 2022 Q1 | 1.02 Billion USD | -8.33% |
| 2022 FY | 710.6 Million USD | -36.39% |
| 2022 Q4 | 710.6 Million USD | -9.01% |
| 2021 Q4 | 1.11 Billion USD | -12.53% |
| 2021 FY | 1.11 Billion USD | -27.4% |
| 2021 Q1 | 1.45 Billion USD | -5.34% |
| 2021 Q2 | 1.37 Billion USD | -5.85% |
| 2021 Q3 | 1.27 Billion USD | -6.86% |
| 2020 Q3 | 1.5 Billion USD | -5.41% |
| 2020 Q2 | 1.59 Billion USD | -15.52% |
| 2020 FY | 1.53 Billion USD | -22.18% |
| 2020 Q4 | 1.53 Billion USD | 2.0% |
| 2020 Q1 | 1.88 Billion USD | -4.52% |
| 2019 FY | 1.97 Billion USD | -8.04% |
| 2019 Q3 | 2.08 Billion USD | -0.54% |
| 2019 Q4 | 1.97 Billion USD | -5.31% |
| 2019 Q1 | 2.16 Billion USD | 0.76% |
| 2019 Q2 | 2.09 Billion USD | -3.08% |
| 2018 Q2 | 2.31 Billion USD | 365.61% |
| 2018 Q4 | 2.15 Billion USD | -4.4% |
| 2018 FY | 2.15 Billion USD | 322.54% |
| 2018 Q1 | 496.79 Million USD | -2.37% |
| 2018 Q3 | 2.24 Billion USD | -2.77% |
| 2017 FY | 508.86 Million USD | -10.55% |
| 2017 Q4 | 508.86 Million USD | -12.57% |
| 2017 Q3 | 582.05 Million USD | 22.32% |
| 2017 Q2 | 475.85 Million USD | -9.96% |
| 2017 Q1 | 528.48 Million USD | -7.1% |
| 2016 Q3 | 425.09 Million USD | -8.21% |
| 2016 Q1 | 491.87 Million USD | -2.03% |
| 2016 Q2 | 463.09 Million USD | -5.85% |
| 2016 FY | 568.87 Million USD | 13.31% |
| 2016 Q4 | 568.87 Million USD | 33.82% |
| 2015 Q4 | 502.06 Million USD | 11.76% |
| 2015 Q1 | 499.21 Million USD | 13.04% |
| 2015 Q3 | 449.24 Million USD | -1.63% |
| 2015 FY | 502.06 Million USD | 13.69% |
| 2015 Q2 | 456.66 Million USD | -8.52% |
| 2014 FY | 441.62 Million USD | 1.63% |
| 2014 Q2 | 478.13 Million USD | -1.82% |
| 2014 Q3 | 476.9 Million USD | -0.26% |
| 2014 Q1 | 487.01 Million USD | 12.08% |
| 2014 Q4 | 441.62 Million USD | -7.4% |
| 2013 Q1 | 447.9 Million USD | -10.02% |
| 2013 Q3 | 383.03 Million USD | -7.21% |
| 2013 FY | 434.52 Million USD | -12.71% |
| 2013 Q4 | 434.52 Million USD | 13.44% |
| 2013 Q2 | 412.8 Million USD | -7.83% |
| 2012 Q3 | 541.45 Million USD | -19.0% |
| 2012 Q1 | 694.78 Million USD | 14.55% |
| 2012 FY | 497.79 Million USD | -17.93% |
| 2012 Q4 | 497.79 Million USD | -8.06% |
| 2012 Q2 | 668.44 Million USD | -3.79% |
| 2011 Q3 | 648.09 Million USD | -3.39% |
| 2011 Q2 | 670.85 Million USD | -4.77% |
| 2011 Q1 | 704.47 Million USD | 35.16% |
| 2011 FY | 606.55 Million USD | 16.37% |
| 2011 Q4 | 606.55 Million USD | -6.41% |
| 2010 Q1 | 548.5 Million USD | -4.69% |
| 2010 FY | 521.22 Million USD | -9.43% |
| 2010 Q4 | 521.22 Million USD | 3.73% |
| 2010 Q3 | 502.47 Million USD | -5.31% |
| 2010 Q2 | 530.63 Million USD | -3.26% |
| 2009 Q2 | 472.99 Million USD | -6.51% |
| 2009 FY | 575.51 Million USD | 2.67% |
| 2009 Q3 | 452.65 Million USD | -4.3% |
| 2009 Q1 | 505.93 Million USD | -9.74% |
| 2009 Q4 | 575.51 Million USD | 27.14% |
| 2008 Q4 | 560.53 Million USD | -1.38% |
| 2008 Q1 | 643.83 Million USD | -11.21% |
| 2008 Q2 | 609.49 Million USD | -5.33% |
| 2008 Q3 | 568.35 Million USD | -6.75% |
| 2008 FY | 560.53 Million USD | -22.7% |
| 2007 Q2 | 703.46 Million USD | -1.44% |
| 2007 Q4 | 725.1 Million USD | -1.79% |
| 2007 Q3 | 738.28 Million USD | 4.95% |
| 2007 FY | 725.1 Million USD | -5.61% |
| 2007 Q1 | 713.74 Million USD | -7.09% |
| 2006 Q1 | 841.53 Million USD | -1.98% |
| 2006 Q3 | 790.02 Million USD | -4.49% |
| 2006 Q4 | 768.17 Million USD | -2.76% |
| 2006 FY | 768.17 Million USD | -10.53% |
| 2006 Q2 | 827.14 Million USD | -1.71% |
| 2005 Q3 | 946.91 Million USD | 36.43% |
| 2005 FY | 858.55 Million USD | 15.25% |
| 2005 Q1 | 714.19 Million USD | -4.13% |
| 2005 Q2 | 694.05 Million USD | -2.82% |
| 2005 Q4 | 858.55 Million USD | -9.33% |
| 2004 FY | 744.92 Million USD | 20.77% |
| 2004 Q4 | 744.92 Million USD | 0.52% |
| 2004 Q3 | 741.1 Million USD | -2.6% |
| 2004 Q2 | 760.91 Million USD | -3.33% |
| 2004 Q1 | 787.13 Million USD | 27.62% |
| 2003 Q2 | 634.49 Million USD | 12.51% |
| 2003 Q1 | 563.94 Million USD | -7.04% |
| 2003 Q3 | 632.92 Million USD | -0.25% |
| 2003 FY | 616.78 Million USD | 1.67% |
| 2003 Q4 | 616.78 Million USD | -2.55% |
| 2002 Q3 | 626.53 Million USD | -4.64% |
| 2002 Q1 | 680.78 Million USD | 2.03% |
| 2002 Q4 | 606.63 Million USD | -3.18% |
| 2002 FY | 606.63 Million USD | -9.08% |
| 2002 Q2 | 657 Million USD | -3.49% |
| 2001 Q1 | 687.14 Million USD | 9.15% |
| 2001 Q2 | 722.69 Million USD | 5.17% |
| 2001 Q3 | 685.68 Million USD | -5.12% |
| 2001 Q4 | 667.24 Million USD | -2.69% |
| 2001 FY | 667.24 Million USD | 5.99% |
| 2000 Q4 | 629.54 Million USD | 49.77% |
| 2000 Q3 | 420.32 Million USD | -3.23% |
| 2000 Q1 | 448.29 Million USD | 97.65% |
| 2000 Q2 | 434.36 Million USD | -3.11% |
| 2000 FY | 629.54 Million USD | 177.57% |
| 1999 Q3 | 121.36 Million USD | -4.2% |
| 1999 Q4 | 226.8 Million USD | 86.87% |
| 1999 Q2 | 126.68 Million USD | -3.55% |
| 1999 Q1 | 131.34 Million USD | -2.34% |
| 1999 FY | 226.8 Million USD | 68.63% |
| 1998 FY | 134.49 Million USD | 12.3% |
| 1998 Q2 | 110.06 Million USD | -3.34% |
| 1998 Q1 | 113.87 Million USD | -4.92% |
| 1998 Q4 | 134.49 Million USD | 31.09% |
| 1998 Q3 | 102.59 Million USD | -6.78% |
| 1997 Q3 | 74.84 Million USD | 0.06% |
| 1997 FY | 119.76 Million USD | 188.58% |
| 1997 Q1 | 73.01 Million USD | 75.94% |
| 1997 Q2 | 74.8 Million USD | 2.44% |
| 1997 Q4 | 119.76 Million USD | 60.01% |
| 1996 Q1 | 21.2 Million USD | -8.62% |
| 1996 Q4 | 41.5 Million USD | 12.77% |
| 1996 Q3 | 36.8 Million USD | -4.91% |
| 1996 FY | 41.5 Million USD | 78.88% |
| 1996 Q2 | 38.7 Million USD | 82.55% |
| 1995 Q3 | 25 Million USD | -6.37% |
| 1995 FY | 23.2 Million USD | 34.88% |
| 1995 Q2 | 26.7 Million USD | -6.32% |
| 1995 Q1 | 28.5 Million USD | 65.7% |
| 1995 Q4 | 23.2 Million USD | -7.2% |
| 1994 FY | 17.2 Million USD | 0.0% |
| 1994 Q2 | 20.9 Million USD | 194.37% |
| 1994 Q3 | 20.3 Million USD | -2.87% |
| 1994 Q1 | 7.1 Million USD | 0.0% |
| 1994 Q4 | 17.2 Million USD | -15.27% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 73.252% |
| Alkermes plc | 2.13 Billion USD | 81.367% |
| Agenus Inc. | 313.91 Million USD | -26.797% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 89.607% |
| Aptorum Group Limited | 20.64 Million USD | -1828.446% |
| Ardelyx, Inc. | 297.57 Million USD | -33.757% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 48.007% |
| Bicycle Therapeutics plc | 595.34 Million USD | 33.142% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -440.057% |
| ChromaDex Corporation | 54.96 Million USD | -624.17% |
| Chimerix, Inc. | 212.77 Million USD | -87.068% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1307.85% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 9.737% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 82.148% |
| Precision BioSciences, Inc. | 159.78 Million USD | -149.112% |
| Dyadic International, Inc. | 8.21 Million USD | -4742.701% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -1154.042% |
| Fortress Biotech, Inc. | 167.52 Million USD | -137.595% |
| Lantern Pharma Inc. | 43.64 Million USD | -811.924% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -146.709% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -2643.797% |
| Incyte Corporation | 6.78 Billion USD | 94.131% |
| IO Biotech, Inc. | 150.71 Million USD | -164.091% |
| Jaguar Health, Inc. | 50.76 Million USD | -684.101% |
| Novavax, Inc. | 1.85 Billion USD | 78.547% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -4.633% |
| Opthea Limited | 188.79 Million USD | -110.832% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 52.221% |
| ContextLogic Inc. | 423 Million USD | 5.902% |
| MiMedx Group, Inc. | 239.04 Million USD | -66.508% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -129.115% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -7599.343% |
| NextCure, Inc. | 129.41 Million USD | -207.556% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -637.809% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -983.702% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -1132.262% |
| Vaxcyte, Inc. | 1.4 Billion USD | 71.729% |
| PDS Biotechnology Corporation | 59.39 Million USD | -570.201% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 37.86% |
| Pharming Group N.V. | 462.85 Million USD | 14.005% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -929.041% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 36.675% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2003.36% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2003.36% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -140.765% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -778.912% |
| Acelyrin, Inc. | 742.69 Million USD | 46.407% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -5943.143% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -6116.352% |
| Summit Therapeutics Inc. | 202.94 Million USD | -96.125% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -435.178% |
| Senti Biosciences, Inc. | 119.48 Million USD | -233.127% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -74.314% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -136.679% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -4717.052% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -8237.921% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 15.166% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -221.895% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -44.766% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 15.821% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -3838.971% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -85.558% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -35056.988% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 3.82% |
| Immix Biopharma, Inc. | 19.92 Million USD | -1897.64% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -7.569% |
| MEI Pharma, Inc. | 41.37 Million USD | -862.013% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1128.269% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -16.794% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -239.546% |
| Fortress Biotech, Inc. | 167.52 Million USD | -137.595% |
| Precigen, Inc. | 151.04 Million USD | -163.523% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1070.066% |
| AlloVir, Inc. | 190.79 Million USD | -108.617% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -5.733% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 21.371% |
| ImmuCell Corporation | 43.8 Million USD | -808.583% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 38.7% |
| Onconetix, Inc. | 88.82 Million USD | -348.127% |
| PureTech Health plc | 693.97 Million USD | 42.644% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -307.466% |
| Elevation Oncology, Inc. | 89.09 Million USD | -346.771% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -6317.817% |
| Seer, Inc. | 436.26 Million USD | 8.764% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -387.803% |
| Innoviva, Inc. | 1.24 Billion USD | 67.991% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -200.577% |
| ESSA Pharma Inc. | 149.12 Million USD | -166.917% |
| GlycoMimetics, Inc. | 45.31 Million USD | -778.341% |
| GT Biopharma, Inc. | 14.1 Million USD | -2721.128% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -29.276% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -64.679% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 15.654% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -685.121% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -318.049% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -62920.988% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 29.718% |
| Aptose Biosciences Inc. | 12.92 Million USD | -2980.144% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -1699.891% |
| Soligenix, Inc. | 9.79 Million USD | -3962.67% |
| Century Therapeutics, Inc. | 360.69 Million USD | -10.353% |
| Kura Oncology, Inc. | 448.93 Million USD | 11.338% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -46.256% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -2201.434% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -258.875% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -94.02% |
| Autolus Therapeutics plc | 375.38 Million USD | -6.034% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -58.178% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -12.064% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -710.13% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 39.795% |
| GRI Bio, Inc. | 2.95 Million USD | -13365.257% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -3653.178% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -133.43% |
| IGM Biosciences, Inc. | 423.41 Million USD | 5.994% |
| INmune Bio, Inc. | 57 Million USD | -598.291% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -78.886% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -374.18% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1424.046% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -5682.678% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -429.116% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -170.296% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -140.498% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 36.78% |
| Verastem, Inc. | 149.71 Million USD | -165.855% |
| Abeona Therapeutics Inc. | 64 Million USD | -521.907% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 22.283% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -157.698% |
| Histogen Inc. | 19.07 Million USD | -1986.892% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -1657.307% |
| Surrozen, Inc. | 46.08 Million USD | -763.787% |
| Organovo Holdings, Inc. | 6.34 Million USD | -6169.223% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -9138.062% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -176.36% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -3272.589% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -428.821% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -4572.16% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -9.66% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -2099.758% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 7.305% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -3056.056% |
| Apollomics, Inc. | 55.38 Million USD | -618.64% |
| Amarin Corporation plc | 831.68 Million USD | 52.141% |
| Mesoblast Limited | 669.15 Million USD | 40.517% |
| Turnstone Biologics Corp. | 112.81 Million USD | -252.819% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 30.868% |
| Synaptogenix, Inc. | 31.11 Million USD | -1179.287% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -3166.85% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 27.374% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -6678.19% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -5318.984% |
| Exelixis, Inc. | 2.94 Billion USD | 86.472% |
| Better Therapeutics, Inc. | 22.94 Million USD | -1634.878% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -9.188% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 49.535% |
| NLS Pharmaceutics AG | 1.84 Million USD | -21454.433% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -4888.736% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -2608.629% |
| Gritstone bio, Inc. | 177.76 Million USD | -123.905% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -317.313% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -2128.345% |
| Avid Bioservices, Inc. | 336.55 Million USD | -18.266% |
| Insmed Incorporated | 1.32 Billion USD | 70.069% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -4033.971% |
| MediWound Ltd. | 66.45 Million USD | -498.915% |
| OmniAb, Inc. | 401.98 Million USD | 0.983% |
| Alector, Inc. | 621.82 Million USD | 35.99% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -10.996% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -7301.134% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -602.097% |
| Zai Lab Limited | 1.03 Billion USD | 61.591% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 16.809% |
| Aura Biosciences, Inc. | 255.07 Million USD | -56.045% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 46.931% |
| Immunic, Inc. | 54.29 Million USD | -633.039% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -49.511% |
| Veracyte, Inc. | 1.13 Billion USD | 65.018% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -3266.661% |
| FibroGen, Inc. | 423.52 Million USD | 6.02% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -11230.288% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -8303.34% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -7230.963% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 96.506% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -4420.534% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 23.079% |
| TG Therapeutics, Inc. | 329.58 Million USD | -20.767% |
| Galecto, Inc. | 38.22 Million USD | -941.235% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -1288.035% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 90.865% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -69.085% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -1502.258% |
| XBiotech Inc. | 227.24 Million USD | -75.157% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -317.313% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -179.126% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -39.213% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -211.282% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -4.197% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 73.305% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -9.097% |
| Vaxxinity, Inc. | 44.35 Million USD | -797.421% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 23.005% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -2038.889% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -30.481% |
| NexImmune, Inc. | 8.59 Million USD | -4531.549% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -3614.661% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -2223.956% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.797% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -1696.897% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -101370.435% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -129.64% |
| Ainos, Inc. | 31.84 Million USD | -1150.033% |
| Pluri Inc. | 39.52 Million USD | -906.99% |
| Prothena Corporation plc | 696.38 Million USD | 42.843% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -40.839% |
| Celularity Inc. | 143.88 Million USD | -176.625% |
| Rallybio Corporation | 115.62 Million USD | -244.26% |
| Cue Biopharma, Inc. | 61.53 Million USD | -546.893% |
| MeiraGTx Holdings plc | 458.16 Million USD | 13.125% |
| Omeros Corporation | 378.26 Million USD | -5.225% |
| Humacyte, Inc. | 128.22 Million USD | -210.422% |
| Immunocore Holdings plc | 597 Million USD | 33.328% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -1173.339% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -480.816% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 62.065% |
| CalciMedica, Inc. | 12.18 Million USD | -3166.582% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -56.922% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -132.893% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -27.97% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 29.589% |
| Pulmatrix, Inc. | 33.95 Million USD | -1072.133% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -1366.268% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -182.577% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 69.405% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -205.735% |
| Cytokinetics, Incorporated | 824.31 Million USD | 51.714% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -1784.358% |
| Nutriband Inc. | 7.51 Million USD | -5194.996% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -404.133% |
| Vor Biopharma Inc. | 209.82 Million USD | -89.695% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 94.489% |
| Evogene Ltd. | 51.1 Million USD | -678.914% |
| ProKidney Corp. | 420.55 Million USD | 5.355% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -625.9% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -4080.897% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 27.151% |
| CorMedix Inc. | 82.05 Million USD | -385.051% |
| BioLineRx Ltd. | 63.92 Million USD | -522.656% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 1.126% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -1311.465% |
| Atai Life Sciences N.V. | 293.47 Million USD | -35.626% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -143.998% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -212.384% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 29.179% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -311.535% |
| MediciNova, Inc. | 66.26 Million USD | -500.623% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -352.578% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -8819.777% |
| GeoVax Labs, Inc. | 9.28 Million USD | -4187.661% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 32.334% |
| Biomea Fusion, Inc. | 199.92 Million USD | -99.089% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 79.086% |
| Mereo BioPharma Group plc | 66.49 Million USD | -498.555% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 17.948% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 35.055% |
| Absci Corporation | 234.48 Million USD | -69.751% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -5341.326% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -17.106% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -141.112% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 24.375% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -43.336% |
| Allakos Inc. | 243.61 Million USD | -63.389% |
| Imunon, Inc. | 21.91 Million USD | -1716.004% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -54.46% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 35.958% |
| BioAtla, Inc. | 119.65 Million USD | -232.642% |
| NLS Pharmaceutics AG | 1.84 Million USD | -21454.433% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -12261.273% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 38.082% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -314.899% |
| XOMA Corporation | 234.3 Million USD | -69.881% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -79.914% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -216.291% |
| aTyr Pharma, Inc. | 122.06 Million USD | -226.077% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -158.626% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 31.406% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 18.839% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -260.312% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -2525.97% |
| Akari Therapeutics, Plc | 4.35 Million USD | -9039.679% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2236.24% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 77.036% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -12806.446% |
| UroGen Pharma Ltd. | 178.31 Million USD | -123.224% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 15.445% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -71525.384% |
| Orgenesis Inc. | 14.55 Million USD | -2635.246% |
| Entera Bio Ltd. | 11.76 Million USD | -3283.196% |
| GH Research PLC | 226.3 Million USD | -75.887% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -627.745% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -270.484% |
| Xencor, Inc. | 952.69 Million USD | 58.22% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -5013.627% |
| Replimune Group, Inc. | 487.72 Million USD | 18.389% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -4831.59% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 38.617% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -12806.446% |
| Portage Biotech Inc. | 7.77 Million USD | -5016.763% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -8819.777% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -43.723% |
| OncoCyte Corporation | 74.89 Million USD | -431.476% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -19476.215% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -6778.479% |
| Purple Biotech Ltd. | 44.3 Million USD | -798.454% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1066.363% |
| scPharmaceuticals Inc. | 94.47 Million USD | -321.293% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -2105.785% |
| HilleVax, Inc. | 344.43 Million USD | -15.561% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -12432.525% |
| Tharimmune, Inc. | 10.94 Million USD | -3536.202% |
| Genprex, Inc. | 10.67 Million USD | -3630.187% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 19.783% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -313.532% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -16306.966% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -9455.603% |
| OKYO Pharma Limited | 1.54 Million USD | -25725.102% |
| Savara Inc. | 177.56 Million USD | -124.163% |
| Curis, Inc. | 77.28 Million USD | -415.04% |
| Daré Bioscience, Inc. | 21.28 Million USD | -1770.261% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -522.424% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -4822.496% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -1954.788% |
| BeiGene, Ltd. | 5.8 Billion USD | 93.144% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -3170.877% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 80.943% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -11.198% |
| Erasca, Inc. | 395.29 Million USD | -0.692% |
| bluebird bio, Inc. | 619.16 Million USD | 35.714% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -9106.547% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 94.182% |
| DBV Technologies S.A. | 182.98 Million USD | -117.521% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -9106.547% |
| Moderna, Inc. | 18.42 Billion USD | 97.84% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -2084.954% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -3335.465% |
| Molecular Templates, Inc. | 35.38 Million USD | -1024.927% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -187.877% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 49.547% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -31.038% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -282.923% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 14.517% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -26.99% |
| MacroGenics, Inc. | 306.82 Million USD | -29.729% |
| RenovoRx, Inc. | 1.46 Million USD | -27050.955% |
| Adicet Bio, Inc. | 207.29 Million USD | -92.013% |
| Prime Medicine, Inc. | 193.85 Million USD | -105.329% |
| Aditxt, Inc. | 44.57 Million USD | -792.885% |
| Adagene Inc. | 115.72 Million USD | -243.936% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -8836.15% |
| Quantum-Si incorporated | 298.25 Million USD | -33.456% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 73.241% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -5063.142% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -13.309% |
| SciSparc Ltd. | 11.18 Million USD | -3459.587% |
| Vericel Corporation | 353.65 Million USD | -12.548% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3159.197% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -599.523% |
| Generation Bio Co. | 374.75 Million USD | -6.211% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -56.296% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -151.019% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -16.6% |
| Invivyd, Inc. | 229.18 Million USD | -73.676% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 52.839% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -3170.796% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -118.232% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -1848.849% |
| 2seventy bio, Inc. | 565.42 Million USD | 29.605% |
| ADMA Biologics, Inc. | 329.18 Million USD | -20.916% |
| Clene Inc. | 52.34 Million USD | -660.461% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -577.684% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -206.429% |
| GeoVax Labs, Inc. | 9.28 Million USD | -4187.661% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 39.111% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -284.16% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -205.273% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -308.021% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -460.634% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -64.101% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 79.693% |
| Evaxion Biotech A/S | 12.88 Million USD | -2988.252% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -57.912% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 47.118% |
| Trevena, Inc. | 40.6 Million USD | -880.256% |
| Surrozen, Inc. | 46.08 Million USD | -763.787% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -76.232% |
| Cingulate Inc. | 3.49 Million USD | -11300.266% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -2293.608% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -505.926% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -3306.467% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -48.234% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 46.855% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -216.17% |
| Clearmind Medicine Inc. | 4.32 Million USD | -9104.375% |
| Kronos Bio, Inc. | 213.27 Million USD | -86.625% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -149.107% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -4549.587% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -8.017% |
| Statera Biopharma, Inc. | 21.16 Million USD | -1780.203% |
| ImmunityBio, Inc. | 504.45 Million USD | 21.096% |
| Korro Bio, Inc. | 221.66 Million USD | -79.567% |
| Kineta, Inc. | 10.28 Million USD | -3771.54% |
| BioVie Inc. | 25.2 Million USD | -1478.973% |
| Codexis, Inc. | 136.56 Million USD | -191.469% |
| Celularity Inc. | 143.88 Million USD | -176.625% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 37.352% |
| Celcuity Inc. | 191.21 Million USD | -108.155% |
| Virax Biolabs Group Limited | 5.48 Million USD | -7158.119% |
| Cibus, Inc. | 544.41 Million USD | 26.887% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -216.165% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -1837.466% |
| IN8bio, Inc. | 33.7 Million USD | -1080.791% |
| Kodiak Sciences Inc. | 479.37 Million USD | 16.968% |
| Annexon, Inc. | 297.67 Million USD | -33.714% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -130.064% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -189.544% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -1796.027% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 86.688% |
| Eyenovia, Inc. | 28.77 Million USD | -1283.05% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -72.661% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -5409.87% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -553.306% |
| Arcellx, Inc. | 825.13 Million USD | 51.761% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -387.564% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 13.897% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -1194.416% |
| Moolec Science SA | 24.05 Million USD | -1554.934% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -28.346% |
| Geron Corporation | 394.07 Million USD | -1.004% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -291.341% |
| Royalty Pharma plc | 16.38 Billion USD | 97.57% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 33.1% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -5590.401% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -3209.408% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -76.074% |
| Humacyte, Inc. | 128.22 Million USD | -210.422% |
| Structure Therapeutics Inc. | 482.01 Million USD | 17.423% |
| 89bio, Inc. | 596.26 Million USD | 33.246% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -57.854% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -21415.297% |
| Genelux Corporation | 27.89 Million USD | -1327.0% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -345.212% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -73.489% |
| Notable Labs, Ltd. | 19.54 Million USD | -1936.912% |
| Liquidia Corporation | 120.43 Million USD | -230.507% |
| Mustang Bio, Inc. | 17.74 Million USD | -2143.451% |
| Immunovant, Inc. | 666.71 Million USD | 40.299% |
| Quantum-Si incorporated | 298.25 Million USD | -33.456% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -175.644% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -634.921% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -126.74% |
| Acasti Pharma Inc. | 73.3 Million USD | -443.019% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -8643.595% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1424.046% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 58.744% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -7569.35% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -1647.215% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -671.337% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -120.284% |
| PepGen Inc. | 143.05 Million USD | -178.244% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -941.508% |
| United Therapeutics Corporation | 7.16 Billion USD | 94.446% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -1974.709% |
| Solid Biosciences Inc. | 164.93 Million USD | -141.321% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -6678.19% |
| Immuneering Corporation | 102.58 Million USD | -288.005% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -9138.062% |
| Silo Pharma, Inc. | 7.74 Million USD | -5038.468% |
| Belite Bio, Inc | 94.64 Million USD | -320.567% |
| XOMA Corporation | 234.3 Million USD | -69.881% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -70.692% |
| Bionomics Limited | 27.64 Million USD | -1339.588% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 0.84% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -270.649% |
| uniQure N.V. | 831.68 Million USD | 52.142% |
| Cassava Sciences, Inc. | 151.66 Million USD | -162.446% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -8836.15% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -45.329% |
| Forte Biosciences, Inc. | 38.98 Million USD | -921.121% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -9672.204% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -980.701% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -5409.87% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -11230.288% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -3267.169% |
| Altimmune, Inc. | 210.64 Million USD | -88.964% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 48.831% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -270.649% |
| Compugen Ltd. | 121.33 Million USD | -228.047% |
| Peak Bio, Inc. | 2.59 Million USD | -15230.099% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -130.975% |
| Benitec Biopharma Inc. | 52.21 Million USD | -662.369% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -16.432% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1044.661% |
| Zura Bio Limited | 100.84 Million USD | -294.706% |
| PolyPid Ltd. | 15.37 Million USD | -2489.338% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -233.68% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1044.661% |
| Instil Bio, Inc. | 325.63 Million USD | -22.235% |
| argenx SE | 4.54 Billion USD | 91.237% |
| Immunome, Inc. | 148.54 Million USD | -167.964% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -153.726% |
| Verona Pharma plc | 308.12 Million USD | -29.179% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -357.725% |
| Shattuck Labs, Inc. | 159.56 Million USD | -149.45% |
| CervoMed Inc. | 9.97 Million USD | -3891.298% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -111.207% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -3395.197% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -121.863% |
| Moolec Science SA | 24.05 Million USD | -1554.934% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -6406.486% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -130.151% |
| AnaptysBio, Inc. | 452.38 Million USD | 12.015% |
| Design Therapeutics, Inc. | 289.64 Million USD | -37.422% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -446.561% |
| NeurAxis, Inc. | 509.49 Thousand USD | -78022.583% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -7246.493% |
| Lumos Pharma, Inc. | 40.63 Million USD | -879.46% |
| Achilles Therapeutics plc | 161.45 Million USD | -146.527% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -357.725% |
| 180 Life Sciences Corp. | 5.25 Million USD | -7467.921% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -465.165% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -4549.587% |
| Nutriband Inc. | 7.51 Million USD | -5194.996% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -56.284% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -99.715% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -422.271% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -587.259% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 24.406% |
| Palisade Bio, Inc. | 14.05 Million USD | -2732.572% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -89.274% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 72.732% |
| Neurogene Inc. | 222.57 Million USD | -78.833% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 38.444% |
| AEON Biopharma, Inc. | 6.84 Million USD | -5714.945% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 12.141% |
| Sesen Bio, Inc. | 189.17 Million USD | -110.406% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -46.407% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -2802.835% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 48.993% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -49.079% |
| Athira Pharma, Inc. | 160.24 Million USD | -148.39% |
| Vaccinex, Inc. | 3.63 Million USD | -10862.077% |
| HCW Biologics Inc. | 28.51 Million USD | -1295.938% |
| XOMA Corporation | 234.3 Million USD | -69.881% |
| Arvinas, Inc. | 1.3 Billion USD | 69.49% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2236.24% |
| Merus N.V. | 458.49 Million USD | 13.187% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -94.765% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -120.879% |
| Rezolute, Inc. | 132.73 Million USD | -199.866% |
| Clene Inc. | 52.34 Million USD | -660.461% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -2567.088% |
| BeyondSpring Inc. | 24.8 Million USD | -1504.454% |
| Synlogic, Inc. | 75.55 Million USD | -426.847% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -3255.53% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -4150.673% |
| Peak Bio, Inc. | 2.59 Million USD | -15230.099% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -127.665% |
| Krystal Biotech, Inc. | 818.35 Million USD | 51.362% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -65.545% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 45.159% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -11027.024% |
| MannKind Corporation | 475.19 Million USD | 16.238% |
| Ikena Oncology, Inc. | 192.09 Million USD | -107.21% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -2876.17% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -241.545% |
| Gossamer Bio, Inc. | 311.91 Million USD | -27.609% |
| CohBar, Inc. | 16.36 Million USD | -2332.122% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1031.965% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -5341.326% |
| Legend Biotech Corporation | 1.84 Billion USD | 78.469% |
| Mural Oncology plc | 301.74 Million USD | -31.91% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -1175.134% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -6907.124% |
| Disc Medicine, Inc. | 367.99 Million USD | -8.162% |
| Champions Oncology, Inc. | 26.13 Million USD | -1423.163% |
| REGENXBIO Inc. | 573.97 Million USD | 30.653% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -14597.951% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -157.817% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -3196.181% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -17.056% |
| Vaxart, Inc. | 91.83 Million USD | -333.445% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -564.453% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -168.348% |
| Cellectis S.A. | 334.27 Million USD | -19.075% |
| Longeveron Inc. | 12.17 Million USD | -3168.46% |
| Repare Therapeutics Inc. | 253.9 Million USD | -56.767% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 87.808% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -98.177% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 80.943% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -24394.338% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -43.326% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -144.045% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -186.883% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -1459.568% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 98.249% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 65.506% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3159.197% |
| Veru Inc. | 50.59 Million USD | -686.69% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -773.78% |
| Cingulate Inc. | 3.49 Million USD | -11300.266% |
| Passage Bio, Inc. | 150.54 Million USD | -164.395% |
| Context Therapeutics Inc. | 16.06 Million USD | -2377.99% |
| Exicure, Inc. | 11.58 Million USD | -3337.245% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -5.846% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -146.244% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -2178.119% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -19.621% |
| Nuvalent, Inc. | 732.38 Million USD | 45.652% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -2563.483% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -344.461% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -2704.827% |
| OmniAb, Inc. | 401.98 Million USD | 0.983% |
| Anew Medical, Inc. | 19.45 Million USD | -1945.816% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -1389.279% |
| Lipocine Inc. | 23 Million USD | -1630.498% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -184.702% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -30.261% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -374.18% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -227.491% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -4916.169% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 54.886% |
| Ocugen, Inc. | 64.54 Million USD | -516.656% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -219.6% |
| Q32 Bio Inc. | 306.11 Million USD | -30.026% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -9358.959% |
| Alumis Inc. Common Stock | 89.61 Million USD | -344.174% |
| Equillium, Inc. | 50.53 Million USD | -687.716% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -429.334% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -864.379% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -23301.964% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -1422.639% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -517.67% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -10579.392% |
| Dominari Holdings Inc. | 57.55 Million USD | -591.534% |
| Edesa Biotech, Inc. | 8.89 Million USD | -4377.092% |
| vTv Therapeutics Inc. | 11.01 Million USD | -3512.57% |
| Bio-Techne Corporation | 2.81 Billion USD | 85.851% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 57.526% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 50.948% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -43.35% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -854.47% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 40.377% |
| Nkarta, Inc. | 378.88 Million USD | -5.054% |
| BioCardia, Inc. | 2.98 Million USD | -13225.511% |
| Iterum Therapeutics plc | 26.25 Million USD | -1415.796% |